Products PHI-101
PHI-101 Phase 1 UNKNOWN 💤 Quiet Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory Acute Myeloid Leukemia
Jun 8, 2020 → May 21, 2022
About PHI-101 PHI-101 is a phase 1 stage product being developed by iBio for Relapsed or Refractory Acute Myeloid Leukemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT04842370. Target conditions include Relapsed or Refractory Acute Myeloid Leukemia.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT04842370 Phase 1 UNKNOWN Jun 8, 2020 May 21, 2022 Relapsed or Refractory Acute Myeloid Leukemia
Competing Products 20 competing products in Relapsed or Refractory Acute Myeloid Leukemia
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3